First molecular analyses have shown that initially treatment with either BRAF monotherapy or BRAF and MEK inhibitors combination (BRAFi/MEKi) initially promote the high expression of melanoma antigen recognized by T-cells 1 (MART-1, MLANA), tyrosinase-related protein 1 and 2 (TYRP-1 and TYRP-2), and melanocyte protein PMEL (GP100), namely melanoma antigens, and promote CD8+ T cell infiltration into the tumor niche. Here, PMEL is linked to melanoma.